This antibody is predicted to react with chimpanzee samples based on sequence homology.
Suggested positive control: human, mouse or rat liver tissue lysate.
AKR1B10, a 316aa protein, catalyzes efficient reduction of aliphatic and aromatic aldehydes. It the first cytosolic NADP (H)-dependent retinal reductase described in humans and is characterized by the presence of a novel NADP binding motif. Due to its ability to convert glucose to sorbitol, AKR1B10 may have a role in development of secondary diabetic complications. It is abundantly expressed in adrenal gland, small intestine and colon, with lower levels in liver, thymus, prostate, testis, and skeletal muscle and its levels are up regulated in certain cancers such as hepatocellular carcinoma.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Protein Aliases: AKR1B10; Aldo-keto reductase family 1 member B10; aldo-keto reductase family 1, member B10; aldo-keto reductase family 1, member B10 (aldose reductase); aldo-keto reductase family 1, member B11 (aldose reductase-like); Aldose reductase-like; aldose reductase-like 1; aldose reductase-like peptide; Aldose reductase-related protein; ARL-1; ARP; hARP; SI reductase; Small intestine reductase
Gene Aliases: 2310005E10Rik; AKR1B10; AKR1B11; AKR1B12; Akr1b16; ALDRLn; ARL-1; ARL1; HIS; HSI
UniProt ID: (Human) O60218